Chemobrain¿podemos hablar de un daño cerebral adquirido por quimioterapia?
- Guadalupe Chiclana Actis
- Francisco Ferre Navarrete
- Sara López-Tarruella Cobo
- Yolanda Jerez Gilarranz
- Iván Márquez Rodas
- Santiago Lizarraga Bonelli
- T. Massarrah
- Miguel Martín Jiménez
ISSN: 1888-6116
Year of publication: 2014
Volume: 25
Issue: 3
Pages: 143-149
Type: Article
More publications in: Trauma
Abstract
Objective: To meet the cognitive impairment caused by chemotherapy in a sample of patients with breast cancer versus controls and themselves, before and after treatment. Material and methods: Prospective longitudinal study. The Mini International Neuropsychiatric Interview was administered and other emotional symptoms like depression, anxiety, sexual function, quality of life and sleep was assessed. Memory, attention, processing speed, working memory, executive function and flow were measured. Both the initial and the final sample were 19 patients and 19 controls. Results: Patients differ in depression, anxiety, quality of life, sexual function, and quality of sleep versus controls at baseline and 6-month. Neurocognitive differences between patients and control group were found in memory before treatment and executive function. After treatment the differences were in memory, executive function and index of prefrontal function. Conclusion: There are significant differences between patients and control group before starting treatment, symptoms of anxiety, depression, quality of life and sleep, sexual function and neurocognitive variables in memory and executive function. After chemotherapy, decline was seen in patients respect control group in: anxiety, depression, and quality of life, quality of sleep and sexual function and cognitive domains of attention, memory, executive function and index of prefrontal function.